These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 12926031)

  • 1. Interactions of fibrinolytic system proteins with lysine-containing surfaces.
    McClung WG; Clapper DL; Anderson AB; Babcock DE; Brash JL
    J Biomed Mater Res A; 2003 Sep; 66(4):795-801. PubMed ID: 12926031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surfaces having dual fibrinolytic and protein resistant properties by immobilization of lysine on polyurethane through a PEG spacer.
    Chen H; Zhang Y; Li D; Hu X; Wang L; McClung WG; Brash JL
    J Biomed Mater Res A; 2009 Sep; 90(3):940-6. PubMed ID: 18646203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lysine-poly(2-hydroxyethyl methacrylate) modified polyurethane surface with high lysine density and fibrinolytic activity.
    Li D; Chen H; Wang S; Wu Z; Brash JL
    Acta Biomater; 2011 Mar; 7(3):954-8. PubMed ID: 20977952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrinolytic properties of lysine-derivatized polyethylene in contact with flowing whole blood (Chandler loop model).
    McClung WG; Babcock DE; Brash JL
    J Biomed Mater Res A; 2007 Jun; 81(3):644-51. PubMed ID: 17187399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysine-PEG-modified polyurethane as a fibrinolytic surface: Effect of PEG chain length on protein interactions, platelet interactions and clot lysis.
    Li D; Chen H; Glenn McClung W; Brash JL
    Acta Biomater; 2009 Jul; 5(6):1864-71. PubMed ID: 19342321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinolytic poly(dimethyl siloxane) surfaces.
    Chen H; Wang L; Zhang Y; Li D; McClung WG; Brook MA; Sheardown H; Brash JL
    Macromol Biosci; 2008 Sep; 8(9):863-70. PubMed ID: 18504801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein-resistant and fibrinolytic polyurethane surfaces.
    Wu Z; Chen H; Liu X; Brash JL
    Macromol Biosci; 2012 Jan; 12(1):126-31. PubMed ID: 21998081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adsorption of plasminogen from human plasma to lysine-containing surfaces.
    McClung WG; Clapper DL; Hu SP; Brash JL
    J Biomed Mater Res; 2000 Mar; 49(3):409-14. PubMed ID: 10602074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions of plasminogen and fibrinogen with model silica glass surfaces: adsorption from plasma and enzymatic activity studies.
    Woodhouse KA; Weitz JI; Brash JL
    J Biomed Mater Res; 1994 Apr; 28(4):407-15. PubMed ID: 8006045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysine-derivatized polyurethane as a clot lysing surface: conversion of adsorbed plasminogen to plasmin and clot lysis in vitro.
    McClung WG; Clapper DL; Hu SP; Brash JL
    Biomaterials; 2001 Jul; 22(13):1919-24. PubMed ID: 11396898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia.
    Sauls DL; Lockhart E; Warren ME; Lenkowski A; Wilhelm SE; Hoffman M
    Biochemistry; 2006 Feb; 45(8):2480-7. PubMed ID: 16489740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
    Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
    Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes.
    Murciano JC; Medinilla S; Eslin D; Atochina E; Cines DB; Muzykantov VR
    Nat Biotechnol; 2003 Aug; 21(8):891-6. PubMed ID: 12845330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding of tissue plasminogen activator to vascular grafts.
    Harvey RA; Kim HC; Pincus J; Trooskin SZ; Wilcox JN; Greco RS
    Thromb Haemost; 1989 Feb; 61(1):131-6. PubMed ID: 2501890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue plasminogen activator-containing polyurethane surfaces for fibrinolytic activity.
    Wu Z; Chen H; Li D; Brash JL
    Acta Biomater; 2011 May; 7(5):1993-8. PubMed ID: 21256990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta2-glycoprotein I, anti-beta2-glycoprotein I, and fibrinolysis.
    Yasuda S; Atsumi T; Ieko M; Koike T
    Thromb Res; 2004; 114(5-6):461-5. PubMed ID: 15507279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corn trypsin inhibitor decreases tissue-type plasminogen activator-mediated fibrinolysis of human plasma.
    Nielsen VG
    Blood Coagul Fibrinolysis; 2009 Apr; 20(3):191-6. PubMed ID: 19657316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of intra-abdominal administration of recombinant tissue plasminogen activator on coagulation, fibrinolysis and inflammatory responses in experimental polymicrobial peritonitis.
    van Veen SQ; Meijers JC; Levi M; van Gulik TM; Boermeester MA
    Shock; 2007 May; 27(5):534-41. PubMed ID: 17438459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The glycocalyx protects erythrocyte-bound tissue-type plasminogen activator from enzymatic inhibition.
    Ganguly K; Murciano JC; Westrick R; Leferovich J; Cines DB; Muzykantov VR
    J Pharmacol Exp Ther; 2007 Apr; 321(1):158-64. PubMed ID: 17215448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
    Guimarães AH; Rijken DC
    Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.